Companies
Positioned at the gateway of academic innovation, Integra invested in game-changing advancements in diverse therapeutic fields that show vast commercial potential, including Oncology, Neurology, Respiratory, Pain & Anesthesia, Infectious Diseases, Inflammation and Ophthalmology. The company holds a portfolio of 11 companies in early to late stages of development
A late stage company with a unique lipid-based cytotoxic agent cytotoxic agent in preparations for review by FDA for marketing authorization.
A biotechnology company devoted to transforming the lives of cancer patients by pioneering the development of next generation immune oncology (IO) therapies.
A preclinical company developing novel antisense oligonucleotides for specific genetic mutations in Cytic Fibrosis, a disease with great unmet clinical needs.
HighRAD provides the first Intelligent Computer Assessment Support (iCASTM) system that delivers a trusted, automatic and enriched view of multi-organ imaging longitudinal data to improve healthcare outcomes and help stop disease progression.
A preclinical company with a unique formulation of the widely used anesthetic agent, Propofol, that provides a solution to the main drawback of the commercial product Diprivan, bacterial contamination.
A preclinical stage company that develops novel liposomal formulations of known drugs for post-surgical pain.
A preclinical company developing novel topical non-invasive formulations of approved drugs to ocular uses, targeting major disease states and clinical needs.
RNAble is a preclinical-stage biotechnology company developing a first-in-class small-molecule FTO inhibitor targeting cancers characterized by chromosomal instability (CIN)
A Phase Ib company that develops a novel liposomal prodrug of a cytotoxic agent for cancer therapy.